← All trials
NCT04405310
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2020
- Primary completion
- Jun 20, 2020
- Completion date
- Jul 20, 2020
- First posted
- May 28, 2020
- Last posted
- May 28, 2020
- Enrollment
- 80
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Grupo Mexicano para el Estudio de la Medicina IntensivaLead sponsor
- Hospital General Naval de Alta EspecialidadCollaborator
- Government of MexicoCollaborator
- Instituto Nacional de Enfermedades RespiratoriasCollaborator
- Grupo Mexicano para el Estudio de la Medicina IntensivaReponsible party - principal investigator
- Hospital General de México Dr. Eduardo LiceagaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.